
Spyre's investigational antibodies are engineered to improve on today’s standard of care – with the goal of getting more patients into deeper remission with therapies that can be delivered less frequently
We are committed to improving treatment options for patients with gastrointestinal and dermatological diseases, aiming to help enhance their quality of life while managing their conditions effectively. Our focus is on developing innovative therapies that target specific aspects of these diseases:
Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by inflammation in the colon and the rectum. Some symptoms may include bloody diarrhea, abdominal pain, bowel urgency, and frequent bowel movements. Approximately 1.3 million individuals in the U.S. have UC, with tens of thousands of new patients diagnosed annually. Despite recent advancements in treatment, a significant number of people living with UC continue to suffer from active disease. Today’s treatments are associated with many challenges, including low rates of remission and a high frequency of injections that may lead to poor compliance.
Crohn’s disease (CD) is a chronic inflammatory disorder characterized by inflammation in any part of the gastrointestinal tract, from the mouth to the rectum. Some symptoms may include abdominal pain, diarrhea, weight loss, fatigue, and complications such as strictures or fistulas. Approximately 1 million individuals in the U.S. have CD, with tens of thousands of new patients diagnosed annually. Despite recent advancements in treatment, a significant number of people living with CD continue to suffer from active disease. Today’s treatments are associated with many challenges, including low rates of remission and a high frequency of injections that may lead to poor compliance.
Hidradenitis suppurativa (HS) is a chronic, immune-mediated inflammatory skin disease that primarily affects areas where skin rubs together, including the underarms, groin, and beneath the breasts. It is characterized by recurrent painful nodules and abscesses that can rupture, drain, form tunnels beneath the skin, and cause permanent scarring, often substantially affecting mobility, mental health, and quality of life. HS may affect approximately 3 million people in the U.S., although prevalence estimates vary widely and the disease is frequently undiagnosed or misdiagnosed. Despite recent advances in treatment, many people living with HS continue to experience active disease. Today’s treatments are associated with significant challenges, including incomplete or loss of response, a limited number of mechanisms of action to cycle through, frequent injections, prolonged antibiotic use, and the need for painful procedures or surgery to address irreversible tunnels and scarring.
Product candidates discussed below are investigational and currently being studied in clinical trials. Their safety and efficacy have not been established and they have not been approved for any use by FDA, the European Commission, or any other health authority.
See our expanded access policy
This study will test the efficacy and safety of our long acting antibodies SPY001, SPY002, SPY003, and long acting combinations SPY120, SPY130, and SPY230 in adult patients with moderate-to-severely active ulcerative colitis. The study is anticipated to include a 12-week induction treatment period followed by a maintenance period.

This study will test the efficacy and safety of our long-acting antibody SPY072 versus placebo in adult patients with moderate-to-severely active HS who are on background SOC (bimekizumab). The study is anticipated to include a 16-week treatment period.